Please use this identifier to cite or link to this item:
Title: Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery applications
Authors: Tran, The-Thien
Nguyen, Minh-Hiep
Tan, Yong Zen
Chew, Jia Wei
Khan, Saif A.
Hadinoto, Kunn
Keywords: Millifluidics
Issue Date: 2017
Source: Tran, T. -T., Nguyen, M. -H., Tan, Y. Z., Chew, J. W., Khan, S. A., & Hadinoto, K. (2016). Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex with tunable size intended for supersaturating drug delivery applications. European Journal of Pharmaceutics and Biopharmaceutics, 112, 196-203.
Series/Report no.: European Journal of Pharmaceutics and Biopharmaceutics
Abstract: The conventional bulk mixing method to prepare amorphous drug-polysaccharide nanoparticle complex (or drug nanoplex in short) has a major drawback in the lack of size control for the nanoplex produced, hence limiting its potential applications as a supersaturating drug delivery system for bioavailability enhancement of poorly soluble drugs. For this reason, we developed a continuous millifluidic synthesis platform of the drug nanoplex exhibiting high size tunability using curcumin (CUR) and chitosan (CHI) as the models for drug and polysaccharides, respectively. The nanoplex size tunability was achieved by controlling the residence time of the CUR and CHI solutions in the millifluidic reactor, where their slow diffusive mixing at the liquid-liquid interface resulted in a well-regulated nanoplex growth as a function of the residence time. The effects of the preparation pH, molecular weight of CHI, millifluidic tube diameter, and flowrate on the nanoplex size tunability were investigated from which the optimal preparation condition was determined. At the optimal condition, the CUR nanoplex was roughly ≈115 nm in size with zeta potential of ≈15 mV and ≈72% (w/w) CUR payload. The millifluidic synthesis also maintained the high CUR utilization rate (≈80%) exhibited by the bulk mixing method. Most importantly, the ability to produce significantly smaller nanoplex (sixfold smaller) via millifluidics led to the generation of higher (≈8.5× of CUR saturation solubility) and prolonged (≈8 h) supersaturation level. These results bode well for the bioavailability enhancement potential of the drug nanoplex.
ISSN: 0939-6411
DOI: 10.1016/j.ejpb.2016.11.030
Rights: © 2016 Elsevier B. V. This is the author created version of a work that has been peer reviewed and accepted for publication by European Journal of Pharmaceutics and Biopharmaceutics, Elsevier. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [].
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SCBE Journal Articles

Files in This Item:
File Description SizeFormat 
Millifluidic synthesis of amorphous drug-polysaccharide nanoparticle complex.pdf308.37 kBAdobe PDFThumbnail

Citations 20

checked on Sep 5, 2020

Citations 50

checked on Oct 19, 2020

Page view(s) 50

checked on Oct 21, 2020

Download(s) 50

checked on Oct 21, 2020

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.